Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,908
archived clinical trials in
Renal Impairment / Chronic Kidney Disease

Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy
A Phase 2 Randomized, Double-blind, Placebo-controlled Study of FG-3019 in Subjects With Type 2 Diabetes Mellitus (DM) and Persistent Proteinuria on Background Angiotensin Converting Enzyme Inhibitor (ACEi) and/or Angiotensin II Receptor Blockade (ARB) Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy
A Phase 2 Randomized, Double-blind, Placebo-controlled Study of FG-3019 in Subjects With Type 2 Diabetes Mellitus (DM) and Persistent Proteinuria on Background Angiotensin Converting Enzyme Inhibitor (ACEi) and/or Angiotensin II Receptor Blockade (ARB) Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy
A Phase 2 Randomized, Double-blind, Placebo-controlled Study of FG-3019 in Subjects With Type 2 Diabetes Mellitus (DM) and Persistent Proteinuria on Background Angiotensin Converting Enzyme Inhibitor (ACEi) and/or Angiotensin II Receptor Blockade (ARB) Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy
A Phase 2 Randomized, Double-blind, Placebo-controlled Study of FG-3019 in Subjects With Type 2 Diabetes Mellitus (DM) and Persistent Proteinuria on Background Angiotensin Converting Enzyme Inhibitor (ACEi) and/or Angiotensin II Receptor Blockade (ARB) Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy
A Phase 2 Randomized, Double-blind, Placebo-controlled Study of FG-3019 in Subjects With Type 2 Diabetes Mellitus (DM) and Persistent Proteinuria on Background Angiotensin Converting Enzyme Inhibitor (ACEi) and/or Angiotensin II Receptor Blockade (ARB) Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Fairfax, VA
Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy
A Phase 2 Randomized, Double-blind, Placebo-controlled Study of FG-3019 in Subjects With Type 2 Diabetes Mellitus (DM) and Persistent Proteinuria on Background Angiotensin Converting Enzyme Inhibitor (ACEi) and/or Angiotensin II Receptor Blockade (ARB) Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Fairfax, VA
Click here to add this to my saved trials
Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy
A Phase 2 Randomized, Double-blind, Placebo-controlled Study of FG-3019 in Subjects With Type 2 Diabetes Mellitus (DM) and Persistent Proteinuria on Background Angiotensin Converting Enzyme Inhibitor (ACEi) and/or Angiotensin II Receptor Blockade (ARB) Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Spokane, WA
Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy
A Phase 2 Randomized, Double-blind, Placebo-controlled Study of FG-3019 in Subjects With Type 2 Diabetes Mellitus (DM) and Persistent Proteinuria on Background Angiotensin Converting Enzyme Inhibitor (ACEi) and/or Angiotensin II Receptor Blockade (ARB) Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Spokane, WA
Click here to add this to my saved trials
Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy
A Phase 2 Randomized, Double-blind, Placebo-controlled Study of FG-3019 in Subjects With Type 2 Diabetes Mellitus (DM) and Persistent Proteinuria on Background Angiotensin Converting Enzyme Inhibitor (ACEi) and/or Angiotensin II Receptor Blockade (ARB) Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Saint Clair Shores, MI
Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy
A Phase 2 Randomized, Double-blind, Placebo-controlled Study of FG-3019 in Subjects With Type 2 Diabetes Mellitus (DM) and Persistent Proteinuria on Background Angiotensin Converting Enzyme Inhibitor (ACEi) and/or Angiotensin II Receptor Blockade (ARB) Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Saint Clair Shores, MI
Click here to add this to my saved trials
Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy
A Phase 2 Randomized, Double-blind, Placebo-controlled Study of FG-3019 in Subjects With Type 2 Diabetes Mellitus (DM) and Persistent Proteinuria on Background Angiotensin Converting Enzyme Inhibitor (ACEi) and/or Angiotensin II Receptor Blockade (ARB) Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Chattanooga, TN
Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy
A Phase 2 Randomized, Double-blind, Placebo-controlled Study of FG-3019 in Subjects With Type 2 Diabetes Mellitus (DM) and Persistent Proteinuria on Background Angiotensin Converting Enzyme Inhibitor (ACEi) and/or Angiotensin II Receptor Blockade (ARB) Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy
Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center, Glomerular Center
mi
from
New York, NY
Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy
Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center, Glomerular Center
mi
from
New York, NY
Click here to add this to my saved trials
Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy
Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center, Nephrology Clinical Research Center
mi
from
New York, NY
Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy
Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center, Nephrology Clinical Research Center
mi
from
New York, NY
Click here to add this to my saved trials
Data Collection for Next Generation Ultrasound Technology Development
Data Collection for Next Generation Ultrasound Technology Development
Status: Enrolling
Updated:  12/31/1969
Research by Design
mi
from
Evergreen Park, IL
Data Collection for Next Generation Ultrasound Technology Development
Data Collection for Next Generation Ultrasound Technology Development
Status: Enrolling
Updated: 12/31/1969
Research by Design
mi
from
Evergreen Park, IL
Click here to add this to my saved trials
Savolitinib vs. Sunitinib in MET-driven PRCC
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
La Jolla, CA
Savolitinib vs. Sunitinib in MET-driven PRCC
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
Savolitinib vs. Sunitinib in MET-driven PRCC
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
Savolitinib vs. Sunitinib in MET-driven PRCC
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Savolitinib vs. Sunitinib in MET-driven PRCC
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Chicago, IL
Savolitinib vs. Sunitinib in MET-driven PRCC
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Savolitinib vs. Sunitinib in MET-driven PRCC
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Iowa City, IA
Savolitinib vs. Sunitinib in MET-driven PRCC
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Iowa City, IA
Click here to add this to my saved trials
Savolitinib vs. Sunitinib in MET-driven PRCC
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Boston, MA
Savolitinib vs. Sunitinib in MET-driven PRCC
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Savolitinib vs. Sunitinib in MET-driven PRCC
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Kansas City, MO
Savolitinib vs. Sunitinib in MET-driven PRCC
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
Savolitinib vs. Sunitinib in MET-driven PRCC
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
New York, NY
Savolitinib vs. Sunitinib in MET-driven PRCC
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Savolitinib vs. Sunitinib in MET-driven PRCC
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Nashville, TN
Savolitinib vs. Sunitinib in MET-driven PRCC
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Savolitinib vs. Sunitinib in MET-driven PRCC
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Status: Enrolling
Updated:  12/31/1969
Research Site
mi
from
Barretos,
Savolitinib vs. Sunitinib in MET-driven PRCC
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Status: Enrolling
Updated: 12/31/1969
Research Site
mi
from
Barretos,
Click here to add this to my saved trials
Safety and Efficacy of Filgotinib and GS-9876 in Adults With Lupus Membranous Nephropathy (LMN)
A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects With Lupus Membranous Nephropathy (LMN)
Status: Enrolling
Updated:  12/31/1969
University of North Carolina at Chapel Hill / UNC School of Medicine
mi
from
Chapel Hill, NC
Safety and Efficacy of Filgotinib and GS-9876 in Adults With Lupus Membranous Nephropathy (LMN)
A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects With Lupus Membranous Nephropathy (LMN)
Status: Enrolling
Updated: 12/31/1969
University of North Carolina at Chapel Hill / UNC School of Medicine
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Safety and Efficacy of Filgotinib and GS-9876 in Adults With Lupus Membranous Nephropathy (LMN)
A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects With Lupus Membranous Nephropathy (LMN)
Status: Enrolling
Updated:  12/31/1969
PMG Research
mi
from
Wilmington, NC
Safety and Efficacy of Filgotinib and GS-9876 in Adults With Lupus Membranous Nephropathy (LMN)
A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects With Lupus Membranous Nephropathy (LMN)
Status: Enrolling
Updated: 12/31/1969
PMG Research
mi
from
Wilmington, NC
Click here to add this to my saved trials
Safety and Efficacy of Filgotinib and GS-9876 in Adults With Lupus Membranous Nephropathy (LMN)
A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects With Lupus Membranous Nephropathy (LMN)
Status: Enrolling
Updated:  12/31/1969
Stanford University
mi
from
Palo Alto, CA
Safety and Efficacy of Filgotinib and GS-9876 in Adults With Lupus Membranous Nephropathy (LMN)
A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects With Lupus Membranous Nephropathy (LMN)
Status: Enrolling
Updated: 12/31/1969
Stanford University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Safety and Efficacy of Filgotinib and GS-9876 in Adults With Lupus Membranous Nephropathy (LMN)
A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects With Lupus Membranous Nephropathy (LMN)
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina University Hospital
mi
from
Charleston, SC
Safety and Efficacy of Filgotinib and GS-9876 in Adults With Lupus Membranous Nephropathy (LMN)
A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects With Lupus Membranous Nephropathy (LMN)
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina University Hospital
mi
from
Charleston, SC
Click here to add this to my saved trials
Safety and Efficacy of Filgotinib and GS-9876 in Adults With Lupus Membranous Nephropathy (LMN)
A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects With Lupus Membranous Nephropathy (LMN)
Status: Enrolling
Updated:  12/31/1969
Metroplex Clinical Research
mi
from
Dallas, TX
Safety and Efficacy of Filgotinib and GS-9876 in Adults With Lupus Membranous Nephropathy (LMN)
A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects With Lupus Membranous Nephropathy (LMN)
Status: Enrolling
Updated: 12/31/1969
Metroplex Clinical Research
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety and Efficacy of Filgotinib and GS-9876 in Adults With Lupus Membranous Nephropathy (LMN)
A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects With Lupus Membranous Nephropathy (LMN)
Status: Enrolling
Updated:  12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Safety and Efficacy of Filgotinib and GS-9876 in Adults With Lupus Membranous Nephropathy (LMN)
A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects With Lupus Membranous Nephropathy (LMN)
Status: Enrolling
Updated: 12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Safety and Efficacy of Filgotinib and GS-9876 in Adults With Lupus Membranous Nephropathy (LMN)
A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects With Lupus Membranous Nephropathy (LMN)
Status: Enrolling
Updated:  12/31/1969
Temple University
mi
from
Philadelphia, PA
Safety and Efficacy of Filgotinib and GS-9876 in Adults With Lupus Membranous Nephropathy (LMN)
A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects With Lupus Membranous Nephropathy (LMN)
Status: Enrolling
Updated: 12/31/1969
Temple University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety and Efficacy of Filgotinib and GS-9876 in Adults With Lupus Membranous Nephropathy (LMN)
A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects With Lupus Membranous Nephropathy (LMN)
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham (UAB)
mi
from
Birmingham, AL
Safety and Efficacy of Filgotinib and GS-9876 in Adults With Lupus Membranous Nephropathy (LMN)
A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects With Lupus Membranous Nephropathy (LMN)
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham (UAB)
mi
from
Birmingham, AL
Click here to add this to my saved trials
Safety and Efficacy of Filgotinib and GS-9876 in Adults With Lupus Membranous Nephropathy (LMN)
A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects With Lupus Membranous Nephropathy (LMN)
Status: Enrolling
Updated:  12/31/1969
University of California, San Diego (UCSD)
mi
from
La Jolla, CA
Safety and Efficacy of Filgotinib and GS-9876 in Adults With Lupus Membranous Nephropathy (LMN)
A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects With Lupus Membranous Nephropathy (LMN)
Status: Enrolling
Updated: 12/31/1969
University of California, San Diego (UCSD)
mi
from
La Jolla, CA
Click here to add this to my saved trials
Safety and Efficacy of Filgotinib and GS-9876 in Adults With Lupus Membranous Nephropathy (LMN)
A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects With Lupus Membranous Nephropathy (LMN)
Status: Enrolling
Updated:  12/31/1969
University of Florida
mi
from
Gainesville, FL
Safety and Efficacy of Filgotinib and GS-9876 in Adults With Lupus Membranous Nephropathy (LMN)
A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects With Lupus Membranous Nephropathy (LMN)
Status: Enrolling
Updated: 12/31/1969
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Safety and Efficacy of Filgotinib and GS-9876 in Adults With Lupus Membranous Nephropathy (LMN)
A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects With Lupus Membranous Nephropathy (LMN)
Status: Enrolling
Updated:  12/31/1969
University of Florida - Jacksonville
mi
from
Jacksonville, FL
Safety and Efficacy of Filgotinib and GS-9876 in Adults With Lupus Membranous Nephropathy (LMN)
A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects With Lupus Membranous Nephropathy (LMN)
Status: Enrolling
Updated: 12/31/1969
University of Florida - Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Safety and Efficacy of Filgotinib and GS-9876 in Adults With Lupus Membranous Nephropathy (LMN)
A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects With Lupus Membranous Nephropathy (LMN)
Status: Enrolling
Updated:  12/31/1969
Univ of Washington
mi
from
Seattle, WA
Safety and Efficacy of Filgotinib and GS-9876 in Adults With Lupus Membranous Nephropathy (LMN)
A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects With Lupus Membranous Nephropathy (LMN)
Status: Enrolling
Updated: 12/31/1969
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Safety and Efficacy of Filgotinib and GS-9876 in Adults With Lupus Membranous Nephropathy (LMN)
A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects With Lupus Membranous Nephropathy (LMN)
Status: Enrolling
Updated:  12/31/1969
Emory University School of Medicine
mi
from
Atlanta, GA
Safety and Efficacy of Filgotinib and GS-9876 in Adults With Lupus Membranous Nephropathy (LMN)
A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects With Lupus Membranous Nephropathy (LMN)
Status: Enrolling
Updated: 12/31/1969
Emory University School of Medicine
mi
from
Atlanta, GA
Click here to add this to my saved trials
Safety and Efficacy of Filgotinib and GS-9876 in Adults With Lupus Membranous Nephropathy (LMN)
A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects With Lupus Membranous Nephropathy (LMN)
Status: Enrolling
Updated:  12/31/1969
Georgia Nephrology Research Institute
mi
from
Lawrenceville, GA
Safety and Efficacy of Filgotinib and GS-9876 in Adults With Lupus Membranous Nephropathy (LMN)
A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects With Lupus Membranous Nephropathy (LMN)
Status: Enrolling
Updated: 12/31/1969
Georgia Nephrology Research Institute
mi
from
Lawrenceville, GA
Click here to add this to my saved trials
Evaluation of the Pharmacokinetics, Safety, and Tolerability of Intravenous ETX2514 and Sulbactam Administered Concurrently to Subjects With Various Degrees of Renal Impairment and Healthy Matched Control Subjects
Evaluation of the Pharmacokinetics, Safety, and Tolerability of Intravenous ETX2514 and Sulbactam Administered Concurrently to Subjects With Various Degrees of Renal Impairment and Healthy Matched Control Subjects
Status: Enrolling
Updated:  12/31/1969
DaVita Clinical Research
mi
from
Lakewood, CO
Evaluation of the Pharmacokinetics, Safety, and Tolerability of Intravenous ETX2514 and Sulbactam Administered Concurrently to Subjects With Various Degrees of Renal Impairment and Healthy Matched Control Subjects
Evaluation of the Pharmacokinetics, Safety, and Tolerability of Intravenous ETX2514 and Sulbactam Administered Concurrently to Subjects With Various Degrees of Renal Impairment and Healthy Matched Control Subjects
Status: Enrolling
Updated: 12/31/1969
DaVita Clinical Research
mi
from
Lakewood, CO
Click here to add this to my saved trials
Evaluation of the Pharmacokinetics, Safety, and Tolerability of Intravenous ETX2514 and Sulbactam Administered Concurrently to Subjects With Various Degrees of Renal Impairment and Healthy Matched Control Subjects
Evaluation of the Pharmacokinetics, Safety, and Tolerability of Intravenous ETX2514 and Sulbactam Administered Concurrently to Subjects With Various Degrees of Renal Impairment and Healthy Matched Control Subjects
Status: Enrolling
Updated:  12/31/1969
DaVita Clinical Research
mi
from
Minneapolis, MN
Evaluation of the Pharmacokinetics, Safety, and Tolerability of Intravenous ETX2514 and Sulbactam Administered Concurrently to Subjects With Various Degrees of Renal Impairment and Healthy Matched Control Subjects
Evaluation of the Pharmacokinetics, Safety, and Tolerability of Intravenous ETX2514 and Sulbactam Administered Concurrently to Subjects With Various Degrees of Renal Impairment and Healthy Matched Control Subjects
Status: Enrolling
Updated: 12/31/1969
DaVita Clinical Research
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Evaluation of the Pharmacokinetics, Safety, and Tolerability of Intravenous ETX2514 and Sulbactam Administered Concurrently to Subjects With Various Degrees of Renal Impairment and Healthy Matched Control Subjects
Evaluation of the Pharmacokinetics, Safety, and Tolerability of Intravenous ETX2514 and Sulbactam Administered Concurrently to Subjects With Various Degrees of Renal Impairment and Healthy Matched Control Subjects
Status: Enrolling
Updated:  12/31/1969
University of Miami, Division of Clinical Pharmacology
mi
from
Miami, FL
Evaluation of the Pharmacokinetics, Safety, and Tolerability of Intravenous ETX2514 and Sulbactam Administered Concurrently to Subjects With Various Degrees of Renal Impairment and Healthy Matched Control Subjects
Evaluation of the Pharmacokinetics, Safety, and Tolerability of Intravenous ETX2514 and Sulbactam Administered Concurrently to Subjects With Various Degrees of Renal Impairment and Healthy Matched Control Subjects
Status: Enrolling
Updated: 12/31/1969
University of Miami, Division of Clinical Pharmacology
mi
from
Miami, FL
Click here to add this to my saved trials
Prebiotics in Peritoneal Dialysis
Prebiotics in Peritoneal Dialysis
Status: Enrolling
Updated:  12/31/1969
DaVita Georgetown Home Training Unit
mi
from
Washington,
Prebiotics in Peritoneal Dialysis
Prebiotics in Peritoneal Dialysis
Status: Enrolling
Updated: 12/31/1969
DaVita Georgetown Home Training Unit
mi
from
Washington,
Click here to add this to my saved trials
Prebiotics in Peritoneal Dialysis
Prebiotics in Peritoneal Dialysis
Status: Enrolling
Updated:  12/31/1969
DaVita K Street
mi
from
Washington,
Prebiotics in Peritoneal Dialysis
Prebiotics in Peritoneal Dialysis
Status: Enrolling
Updated: 12/31/1969
DaVita K Street
mi
from
Washington,
Click here to add this to my saved trials
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of FAST PV and mGFR Technology™
A Phase 2b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of FAST PV and mGFR Technology™ in Healthy Subjects and Patients With Varying Degrees of Renal Impairment
Status: Enrolling
Updated:  12/31/1969
University of Alabama Birmingham, Division of Nephrology
mi
from
Birmingham, AL
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of FAST PV and mGFR Technology™
A Phase 2b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of FAST PV and mGFR Technology™ in Healthy Subjects and Patients With Varying Degrees of Renal Impairment
Status: Enrolling
Updated: 12/31/1969
University of Alabama Birmingham, Division of Nephrology
mi
from
Birmingham, AL
Click here to add this to my saved trials
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of FAST PV and mGFR Technology™
A Phase 2b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of FAST PV and mGFR Technology™ in Healthy Subjects and Patients With Varying Degrees of Renal Impairment
Status: Enrolling
Updated:  12/31/1969
ICON Early Phase Services
mi
from
San Antonio, TX
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of FAST PV and mGFR Technology™
A Phase 2b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of FAST PV and mGFR Technology™ in Healthy Subjects and Patients With Varying Degrees of Renal Impairment
Status: Enrolling
Updated: 12/31/1969
ICON Early Phase Services
mi
from
San Antonio, TX
Click here to add this to my saved trials
Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis
Status: Enrolling
Updated:  12/31/1969
Investigative Site: #44
mi
from
Phoenix, AZ
Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis
Status: Enrolling
Updated: 12/31/1969
Investigative Site: #44
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis
Status: Enrolling
Updated:  12/31/1969
Investigative Site 56
mi
from
Chula Vista, CA
Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis
Status: Enrolling
Updated: 12/31/1969
Investigative Site 56
mi
from
Chula Vista, CA
Click here to add this to my saved trials
Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis
Status: Enrolling
Updated:  12/31/1969
Investigative Site #04
mi
from
Los Angeles, CA
Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis
Status: Enrolling
Updated: 12/31/1969
Investigative Site #04
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis
Status: Enrolling
Updated:  12/31/1969
Investigative Site 048
mi
from
Hialeah, FL
Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis
Status: Enrolling
Updated: 12/31/1969
Investigative Site 048
mi
from
Hialeah, FL
Click here to add this to my saved trials
Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis
Status: Enrolling
Updated:  12/31/1969
Investigative Site 54
mi
from
Hollywood, FL
Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis
Status: Enrolling
Updated: 12/31/1969
Investigative Site 54
mi
from
Hollywood, FL
Click here to add this to my saved trials
Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis
Status: Enrolling
Updated:  12/31/1969
Investigative Site 92
mi
from
Lauderdale Lakes, FL
Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis
Status: Enrolling
Updated: 12/31/1969
Investigative Site 92
mi
from
Lauderdale Lakes, FL
Click here to add this to my saved trials
Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis
Status: Enrolling
Updated:  12/31/1969
Investigative Site 017
mi
from
Tampa, FL
Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis
Status: Enrolling
Updated: 12/31/1969
Investigative Site 017
mi
from
Tampa, FL
Click here to add this to my saved trials
Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis
Status: Enrolling
Updated:  12/31/1969
Investigative Site 57
mi
from
Winter Park, FL
Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis
Status: Enrolling
Updated: 12/31/1969
Investigative Site 57
mi
from
Winter Park, FL
Click here to add this to my saved trials
Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis
Status: Enrolling
Updated:  12/31/1969
Investigative Site 022
mi
from
Atlanta, GA
Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis
Status: Enrolling
Updated: 12/31/1969
Investigative Site 022
mi
from
Atlanta, GA
Click here to add this to my saved trials
Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis
Status: Enrolling
Updated:  12/31/1969
Investigative Site 018
mi
from
Shreveport, LA
Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis
Status: Enrolling
Updated: 12/31/1969
Investigative Site 018
mi
from
Shreveport, LA
Click here to add this to my saved trials
Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis
Status: Enrolling
Updated:  12/31/1969
Investigative Site 58
mi
from
Flushing, NY
Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis
Status: Enrolling
Updated: 12/31/1969
Investigative Site 58
mi
from
Flushing, NY
Click here to add this to my saved trials